Company Information & Drug Savings for Madrigal Pharmaceuticals, Inc. Medications
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. The company created Rezdiffra (resmetirom), the first FDA-approved treatment for NASH, a serious liver condition associated with obesity and metabolic syndrome. Madrigal’s thyroid hormone receptor-beta agonist represents a breakthrough in fatty liver disease treatment.
How to Contact Madrigal Pharmaceuticals, Inc.
Phone
1-267-824-2827Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
